Mga Batayang Estadistika
| LEI | 549300JFUK6FRD5MH739 |
| CIK | 1651308 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to BeOne Medicines AG - Depositary Receipt (Common Stock)
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 29, 2025 BEONE MEDICINES LTD. (Exact Name of Registrant as Specified in Charter) Switzerland 001-37686 98-1209416 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| August 29, 2025 |
Exhibit 99.1 Financial Information On August 29, 2025, BeOne Medicines Ltd. (the “Company”) filed its 2025 Interim Report for the six months ended June 30, 2025 (the “STAR Interim Report”) with the Science and Technology Innovation Board (the “STAR Market”) of the Shanghai Stock Exchange, which was prepared in accordance with the listing rules of the STAR Market and the applicable securities laws |
|
| August 25, 2025 |
BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million Exhibit 99.1 BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million •Royalty Pharma to acquire rights to BeOne’s royalties on IMDELLTRA® (tarlatamab-dlle) worldwide (ex-China) sales for up to $950 million •IMDELLTRA is a first-in-class DLL-3 targeting bispecific T-cell engager, indicated for the treatment of adult patients with extensive-stage small cell lung cancer |
|
| August 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 25, 2025 BEONE MEDICINES LTD. (Exact Name of Registrant as Specified in Charter) Switzerland 001-37686 98-1209416 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| August 6, 2025 |
May 9, 2025 BeiGene Switzerland GmbH Aeschengraben 27 4051 Basel Switzerland Attention: Managing Director BeOne Medicines USA, Inc. |
|
| August 6, 2025 |
Fifth Amended and Restated 2018 Employee Share Purchase Plan Exhibit 10.18 BEONE MEDICINES LTD. FIFTH AMENDED AND RESTATED 2018 EMPLOYEE SHARE PURCHASE PLAN The purpose of the BeOne Medicines Ltd. Fifth Amended and Restated 2018 Employee Share Purchase Plan (the “Plan”) is to provide the Participants (as defined in Section 1) with opportunities to purchase Shares (either in the form of Ordinary Shares or ADSs). The Plan includes two components: a Code Secti |
|
| August 6, 2025 |
Exhibit 99.1 BeOne Medicines Announces Second Quarter 2025 Financial Results and Business Updates •Second quarter total revenues increased 42% to $1.3 billion versus second quarter 2024 •Global BRUKINSA revenues increased 49% to $950 million versus second quarter 2024 •Reported diluted GAAP Earnings per American Depositary Share (ADS) of $0.84, non-GAAP diluted Earnings per ADS of $2.25 •Anticipat |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37686 BEONE MEDI |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 6, 2025 BEONE MEDICINES LTD. (Exact Name of Registrant as Specified in Charter) Switzerland 001-37686 98-1209416 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 27, 2025 |
Exhibit 99.2.2 CERTAIN INFORMATION (INDICATED BY “[…***…]”) AND SCHEDULES HAVE BEEN EXCLUDED FROM THIS AGREEMENT BECAUSE SUCH INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. GLOBAL performance SHARE UNIT AWARD AGREEMENT UNDER beone medicines Ltd. 2016 Share OPTION AND INCENTIVE PLAN Name of Grantee: Target Number of PSUs Granted: Grant Date: Pursuant |
|
| May 27, 2025 |
Exhibit 99.2.8 GLOBAL NON-QUALIFIED SHARE OPTION AGREEMENT FOR NON-EMPLOYEE Consultants UNDER BeONE Medicines LTD. 2016 SHARE OPTION AND INCENTIVE PLAN Name of Optionee: No. of Option Shares: Ordinary Shares (as defined below) Option Exercise Price per Share: $ [Must be the higher of (a) 1/13 of the closing price of the Company’s ADSs as quoted on the NASDAQ on the date of grant, and (b) 1/13 of |
|
| May 27, 2025 |
2011 Option Plan, as amended and form of option agreement thereunder Exhibit 99.1 BeiGene, LTD 2011 OPTION PLAN (the “Plan”) SECTION 1. GENERAL PURPOSE; DEFINITIONS The purpose of this Plan is to enable persons providing (or expected to provide) services to BeiGene, Ltd. (a Cayman Islands exempted company incorporated with limited liability hereinafter referred to as the “Company”) and its Subsidiaries to acquire ordinary shares in the Company. |
|
| May 27, 2025 |
As filed with the U.S. Securities and Exchange Commission on May 27, 2025 As filed with the U.S. Securities and Exchange Commission on May 27, 2025 Registration No. 333-281324 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 to FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BeOne Medicines Ltd. (Exact name of registrant as specified in its charter) Switzerland 2834 98-1209416 (State or other jurisdi |
|
| May 27, 2025 |
Exhibit 4.1.5 BeOne Medicines Ltd. Amended and Restated as of May 27, 2025 Citibank, N.A. – ADR Department 388 Greenwich Street New York, New York 10013 Attention: Account Management BeOne Medicines Ltd. (CUSIP No.: 07725L987) Dear Sirs: Reference is hereby made to (i) the Amended and Restated Deposit Agreement, dated as of May 27, 2025, as may be amended and supplemented from time to time (the “D |
|
| May 27, 2025 |
Exhibit 99.2.5 GLOBAL RESTRICTED SHARE UNIT AWARD AGREEMENT FOR CONSULTANTS UNDER BEONE MEDICINES LTD. 2016 SHARE OPTION AND INCENTIVE PLAN Name of Grantee: No. of Restricted Share Units: Grant Date: Pursuant to the BeOne Medicines Ltd. 2016 Share Option and Incentive Plan as amended through the Grant Date (the “Plan”), and this Global Restricted share Unit Award Agreement for Consultants, includi |
|
| May 27, 2025 |
Fourth Amended and Restated 2016 Share Option and Incentive Plan Exhibit 99.2.1 BEONE MEDICINES LTD. FOURTH AMENDED AND RESTATED 2016 SHARE OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the BeOne Medicines Ltd. Fourth Amended and Restated 2016 Share Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consul |
|
| May 27, 2025 |
Exhibit 10.7 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (this “Consulting Agreement”), effective as of the Effective Date, as defined below, is entered into by BeOne Medicines USA, Inc., a corporation incorporated under the laws of the State of Delaware (the “Company”), and Xiaodong Wang (the “Consultant”) (the Company and the Consultant each a “Party” and together the “Parties”). WHEREAS, the |
|
| May 27, 2025 |
Exhibit 99.2.3 GLOBAL RESTRICTED Share UNIT AWARD AGREEMENT FOR NON-EMPLOYEE DIRECTORS UNDER beone medicines Ltd. 2016 Share OPTION AND INCENTIVE PLAN Name of Grantee: No. of Restricted Share Units: Grant Date: Pursuant to the BeOne Medicines Ltd. 2016 Share Option and Incentive Plan, as amended through the Grant Date (the “Plan”), and this Global Restricted Share Unit Award Agreement for No |
|
| May 27, 2025 |
Fourth Amended and Restated 2016 Share Option and Incentive Plan Exhibit 99.2.1 BEONE MEDICINES LTD. FOURTH AMENDED AND RESTATED 2016 SHARE OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the BeOne Medicines Ltd. Fourth Amended and Restated 2016 Share Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consul |
|
| May 27, 2025 |
Organizational Regulations of the Registrant, as currently in effect Exhibit 3.2 Organizational Regulations dated as of May 27, 2025 of BeOne Medicines Ltd. a Swiss corporation with its registered office in Basel, Canton of Basel-Stadt, Switzerland 1. Scope and Basis (a) These Organizational Regulations (the Regulations) are enacted by the board of directors (the Board) of BeOne Medicines Ltd. (the Company) pursuant to Article 716b of the Swiss Code of Obligations, |
|
| May 27, 2025 |
Exhibit 99.2.3 GLOBAL RESTRICTED Share UNIT AWARD AGREEMENT FOR NON-EMPLOYEE DIRECTORS UNDER beone medicines Ltd. 2016 Share OPTION AND INCENTIVE PLAN Name of Grantee: No. of Restricted Share Units: Grant Date: Pursuant to the BeOne Medicines Ltd. 2016 Share Option and Incentive Plan, as amended through the Grant Date (the “Plan”), and this Global Restricted Share Unit Award Agreement for No |
|
| May 27, 2025 |
Exhibit 4.1.1 AMENDED AND RESTATED DEPOSIT AGREEMENT by and among BeOne Medicines Ltd. and CITIBANK, N.A., as Depositary, and ALL HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES ISSUED HEREUNDER Dated as of May 27, 2025 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 Section 1.1. “ADS Record Date” 1 Section 1.2. “Affiliate” 1 Section 1.3. “American Depositary Receipt(s)”, “ADR(s)” and “ |
|
| May 27, 2025 |
2011 Option Plan, as amended and form of option agreement thereunder Exhibit 99.1 BeiGene, LTD 2011 OPTION PLAN (the “Plan”) SECTION 1. GENERAL PURPOSE; DEFINITIONS The purpose of this Plan is to enable persons providing (or expected to provide) services to BeiGene, Ltd. (a Cayman Islands exempted company incorporated with limited liability hereinafter referred to as the “Company”) and its Subsidiaries to acquire ordinary shares in the Company. |
|
| May 27, 2025 |
2011 Option Plan, as amended and form of option agreement thereunder Exhibit 99.1 BeiGene, LTD 2011 OPTION PLAN (the “Plan”) SECTION 1. GENERAL PURPOSE; DEFINITIONS The purpose of this Plan is to enable persons providing (or expected to provide) services to BeiGene, Ltd. (a Cayman Islands exempted company incorporated with limited liability hereinafter referred to as the “Company”) and its Subsidiaries to acquire ordinary shares in the Company. |
|
| May 27, 2025 |
As filed with the U.S. Securities and Exchange Commission on May 27, 2025 As filed with the U.S. Securities and Exchange Commission on May 27, 2025 Registration No. 333-209410 Registration No. 333-214064 Registration No. 333-216885 Registration No. 333-223319 Registration No. 333-225543 Registration No. 333-228786 Registration No. 333-241697 Registration No. 333-266639 Registration No. 333-279980 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 PO |
|
| May 27, 2025 |
As filed with the U.S. Securities and Exchange Commission on May 27, 2025 As filed with the U.S. Securities and Exchange Commission on May 27, 2025 Registration No. 333-209410 Registration No. 333-214064 Registration No. 333-216885 Registration No. 333-223319 Registration No. 333-225543 Registration No. 333-228786 Registration No. 333-241697 Registration No. 333-266639 Registration No. 333-279980 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 PO |
|
| May 27, 2025 |
As filed with the U.S. Securities and Exchange Commission on May 27, 2025 As filed with the U.S. Securities and Exchange Commission on May 27, 2025 Registration No. 333-209410 Registration No. 333-214064 Registration No. 333-216885 Registration No. 333-223319 Registration No. 333-225543 Registration No. 333-228786 Registration No. 333-241697 Registration No. 333-266639 Registration No. 333-279980 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 PO |
|
| May 27, 2025 |
Exhibit 99.2.3 GLOBAL RESTRICTED Share UNIT AWARD AGREEMENT FOR NON-EMPLOYEE DIRECTORS UNDER beone medicines Ltd. 2016 Share OPTION AND INCENTIVE PLAN Name of Grantee: No. of Restricted Share Units: Grant Date: Pursuant to the BeOne Medicines Ltd. 2016 Share Option and Incentive Plan, as amended through the Grant Date (the “Plan”), and this Global Restricted Share Unit Award Agreement for No |
|
| May 27, 2025 |
Exhibit 4.7 BEONE MEDICINES LTD., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 202[●] Subordinated Debt Securities TABLE OF CONTENTS1 Article 1 DEFINITIONS 1 Section 1.1 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.1 Designation and Terms of Securities 5 Section 2 |
|
| May 27, 2025 |
Exhibit 99.2.2 CERTAIN INFORMATION (INDICATED BY “[…***…]”) AND SCHEDULES HAVE BEEN EXCLUDED FROM THIS AGREEMENT BECAUSE SUCH INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. GLOBAL performance SHARE UNIT AWARD AGREEMENT UNDER beone medicines Ltd. 2016 Share OPTION AND INCENTIVE PLAN Name of Grantee: Target Number of PSUs Granted: Grant Date: Pursuant |
|
| May 27, 2025 |
Exhibit 99.2.6 GLOBAL NON-QUALIFIED Share OPTION AGREEMENT FOR EMPLOYEES UNDER BEONE MEDICINES LTD. 2016 SHARE OPTION AND INCENTIVE PLAN Name of Optionee: No. of Option Shares: Ordinary Shares (as defined below) Option Exercise Price per Share: $ [Must be the higher of (a) 1/13 of the closing price of the Company’s ADSs as quoted on the NASDAQ on the date of grant, and (b) 1/13 of the average clos |
|
| May 27, 2025 |
Exhibit 99.2.4 GLOBAL RESTRICTED Share UNIT AWARD AGREEMENT FOR EMPLOYEES UNDER BeOne Medicines Ltd. 2016 Share OPTION AND INCENTIVE PLAN Name of Grantee: No. of Restricted Share Units: Grant Date: Pursuant to the BeOne Medicines Ltd. 2016 Share Option and Incentive Plan, as amended through the Grant Date (the “Plan”), and this Global Restricted Share Unit Award Agreement for Employees, including |
|
| May 27, 2025 |
Fifth Amended and Restated 2018 Employee Share Purchase Plan Exhibit 99.3 BEONE MEDICINES LTD. FIFTH AMENDED AND RESTATED 2018 EMPLOYEE SHARE PURCHASE PLAN The purpose of the BeOne Medicines Ltd. Fifth Amended and Restated 2018 Employee Share Purchase Plan (the “Plan”) is to provide the Participants (as defined in Section 1) with opportunities to purchase Shares (either in the form of Ordinary Shares or ADSs). The Plan includes two components: a Code Sectio |
|
| May 27, 2025 |
2011 Option Plan, as amended and form of option agreement thereunder Exhibit 99.1 BeiGene, LTD 2011 OPTION PLAN (the “Plan”) SECTION 1. GENERAL PURPOSE; DEFINITIONS The purpose of this Plan is to enable persons providing (or expected to provide) services to BeiGene, Ltd. (a Cayman Islands exempted company incorporated with limited liability hereinafter referred to as the “Company”) and its Subsidiaries to acquire ordinary shares in the Company. |
|
| May 27, 2025 |
As filed with the U.S. Securities and Exchange Commission on May 27, 2025 As filed with the U.S. Securities and Exchange Commission on May 27, 2025 Registration No. 333-271762 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 to FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BeOne Medicines Ltd. (Exact name of registrant as specified in its charter) Switzerland (State or other jurisdiction of incorpo |
|
| May 27, 2025 |
As filed with the U.S. Securities and Exchange Commission on May 27, 2025 As filed with the U.S. Securities and Exchange Commission on May 27, 2025 Registration No. 333-209410 Registration No. 333-214064 Registration No. 333-216885 Registration No. 333-223319 Registration No. 333-225543 Registration No. 333-228786 Registration No. 333-241697 Registration No. 333-266639 Registration No. 333-279980 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 PO |
|
| May 27, 2025 |
Exhibit 99.2.4 GLOBAL RESTRICTED Share UNIT AWARD AGREEMENT FOR EMPLOYEES UNDER BeOne Medicines Ltd. 2016 Share OPTION AND INCENTIVE PLAN Name of Grantee: No. of Restricted Share Units: Grant Date: Pursuant to the BeOne Medicines Ltd. 2016 Share Option and Incentive Plan, as amended through the Grant Date (the “Plan”), and this Global Restricted Share Unit Award Agreement for Employees, including |
|
| May 27, 2025 |
Exhibit 99.2.3 GLOBAL RESTRICTED Share UNIT AWARD AGREEMENT FOR NON-EMPLOYEE DIRECTORS UNDER beone medicines Ltd. 2016 Share OPTION AND INCENTIVE PLAN Name of Grantee: No. of Restricted Share Units: Grant Date: Pursuant to the BeOne Medicines Ltd. 2016 Share Option and Incentive Plan, as amended through the Grant Date (the “Plan”), and this Global Restricted Share Unit Award Agreement for No |
|
| May 27, 2025 |
Exhibit 99.2.3 GLOBAL RESTRICTED Share UNIT AWARD AGREEMENT FOR NON-EMPLOYEE DIRECTORS UNDER beone medicines Ltd. 2016 Share OPTION AND INCENTIVE PLAN Name of Grantee: No. of Restricted Share Units: Grant Date: Pursuant to the BeOne Medicines Ltd. 2016 Share Option and Incentive Plan, as amended through the Grant Date (the “Plan”), and this Global Restricted Share Unit Award Agreement for No |
|
| May 27, 2025 |
Fourth Amended and Restated 2016 Share Option and Incentive Plan Exhibit 99.2.1 BEONE MEDICINES LTD. FOURTH AMENDED AND RESTATED 2016 SHARE OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the BeOne Medicines Ltd. Fourth Amended and Restated 2016 Share Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consul |
|
| May 27, 2025 |
Exhibit 99.2.6 GLOBAL NON-QUALIFIED Share OPTION AGREEMENT FOR EMPLOYEES UNDER BEONE MEDICINES LTD. 2016 SHARE OPTION AND INCENTIVE PLAN Name of Optionee: No. of Option Shares: Ordinary Shares (as defined below) Option Exercise Price per Share: $ [Must be the higher of (a) 1/13 of the closing price of the Company’s ADSs as quoted on the NASDAQ on the date of grant, and (b) 1/13 of the average clos |
|
| May 27, 2025 |
Exhibit 10.3 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement is entered into by and between BeOne Medicines USA, Inc., a company incorporated under the laws of the State of Delaware (the “Company”), and Aaron Rosenberg (the “Executive”) (the Company and the Executive are each referred to as a “Party” and together as the “Parties”), effective as of the Effective Date (this “Agree |
|
| May 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K12G3 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2025 BEONE MEDICINES LTD. (Exact name of registrant as specified in its charter) Switzerland 001-37686 98-1209416 (State or other jurisdiction of incorporation) (Commissio |
|
| May 27, 2025 |
Exhibit 99.2.3 GLOBAL RESTRICTED Share UNIT AWARD AGREEMENT FOR NON-EMPLOYEE DIRECTORS UNDER beone medicines Ltd. 2016 Share OPTION AND INCENTIVE PLAN Name of Grantee: No. of Restricted Share Units: Grant Date: Pursuant to the BeOne Medicines Ltd. 2016 Share Option and Incentive Plan, as amended through the Grant Date (the “Plan”), and this Global Restricted Share Unit Award Agreement for No |
|
| May 27, 2025 |
Exhibit 99.2.8 GLOBAL NON-QUALIFIED SHARE OPTION AGREEMENT FOR NON-EMPLOYEE Consultants UNDER BeONE Medicines LTD. 2016 SHARE OPTION AND INCENTIVE PLAN Name of Optionee: No. of Option Shares: Ordinary Shares (as defined below) Option Exercise Price per Share: $ [Must be the higher of (a) 1/13 of the closing price of the Company’s ADSs as quoted on the NASDAQ on the date of grant, and (b) 1/13 of |
|
| May 27, 2025 |
Exhibit 10.2 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement is entered into by and between BeOne Medicines (Beijing) Co., Ltd., a company incorporated under the laws of the People’s Republic of China (the “Company”), and Dr. Wu Xiaobin (the “Executive”) (the Company and the Executive are each referred to as a “Party” and together as the “Parties”), effective as of the Effective |
|
| May 27, 2025 |
Fourth Amended and Restated 2016 Share Option and Incentive Plan Exhibit 99.2.1 BEONE MEDICINES LTD. FOURTH AMENDED AND RESTATED 2016 SHARE OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the BeOne Medicines Ltd. Fourth Amended and Restated 2016 Share Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consul |
|
| May 27, 2025 |
Fifth Amended and Restated 2018 Employee Share Purchase Plan Exhibit 99.3 BEONE MEDICINES LTD. FIFTH AMENDED AND RESTATED 2018 EMPLOYEE SHARE PURCHASE PLAN The purpose of the BeOne Medicines Ltd. Fifth Amended and Restated 2018 Employee Share Purchase Plan (the “Plan”) is to provide the Participants (as defined in Section 1) with opportunities to purchase Shares (either in the form of Ordinary Shares or ADSs). The Plan includes two components: a Code Sectio |
|
| May 27, 2025 |
Exhibit 99.2.8 GLOBAL NON-QUALIFIED SHARE OPTION AGREEMENT FOR NON-EMPLOYEE Consultants UNDER BeONE Medicines LTD. 2016 SHARE OPTION AND INCENTIVE PLAN Name of Optionee: No. of Option Shares: Ordinary Shares (as defined below) Option Exercise Price per Share: $ [Must be the higher of (a) 1/13 of the closing price of the Company’s ADSs as quoted on the NASDAQ on the date of grant, and (b) 1/13 of |
|
| May 27, 2025 |
Exhibit 99.2.5 GLOBAL RESTRICTED SHARE UNIT AWARD AGREEMENT FOR CONSULTANTS UNDER BEONE MEDICINES LTD. 2016 SHARE OPTION AND INCENTIVE PLAN Name of Grantee: No. of Restricted Share Units: Grant Date: Pursuant to the BeOne Medicines Ltd. 2016 Share Option and Incentive Plan as amended through the Grant Date (the “Plan”), and this Global Restricted share Unit Award Agreement for Consultants, includi |
|
| May 27, 2025 |
List of Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries Name of Subsidiary Jurisdiction of Incorporation or Organization Percentage of Ownership by the Registrant BeiGene 101 Cayman Islands 100% BeiGene Argentina S.R.L. Argentina 100% BeiGene AUS Pty Ltd Australia 100% BeOne Medicines (Beijing) Co., Ltd. People’s Republic of China 100% BeiGene Belgium SRL Belgium 100% BeOne Biologics Co., Ltd. People’s Republic of China 100% B |
|
| May 27, 2025 |
Fifth Amended and Restated 2018 Employee Share Purchase Plan Exhibit 99.3 BEONE MEDICINES LTD. FIFTH AMENDED AND RESTATED 2018 EMPLOYEE SHARE PURCHASE PLAN The purpose of the BeOne Medicines Ltd. Fifth Amended and Restated 2018 Employee Share Purchase Plan (the “Plan”) is to provide the Participants (as defined in Section 1) with opportunities to purchase Shares (either in the form of Ordinary Shares or ADSs). The Plan includes two components: a Code Sectio |
|
| May 27, 2025 |
Fifth Amended and Restated 2018 Employee Share Purchase Plan Exhibit 99.3 BEONE MEDICINES LTD. FIFTH AMENDED AND RESTATED 2018 EMPLOYEE SHARE PURCHASE PLAN The purpose of the BeOne Medicines Ltd. Fifth Amended and Restated 2018 Employee Share Purchase Plan (the “Plan”) is to provide the Participants (as defined in Section 1) with opportunities to purchase Shares (either in the form of Ordinary Shares or ADSs). The Plan includes two components: a Code Sectio |
|
| May 27, 2025 |
Fifth Amended and Restated 2018 Employee Share Purchase Plan Exhibit 99.3 BEONE MEDICINES LTD. FIFTH AMENDED AND RESTATED 2018 EMPLOYEE SHARE PURCHASE PLAN The purpose of the BeOne Medicines Ltd. Fifth Amended and Restated 2018 Employee Share Purchase Plan (the “Plan”) is to provide the Participants (as defined in Section 1) with opportunities to purchase Shares (either in the form of Ordinary Shares or ADSs). The Plan includes two components: a Code Sectio |
|
| May 27, 2025 |
Exhibit 99.2.5 GLOBAL RESTRICTED SHARE UNIT AWARD AGREEMENT FOR CONSULTANTS UNDER BEONE MEDICINES LTD. 2016 SHARE OPTION AND INCENTIVE PLAN Name of Grantee: No. of Restricted Share Units: Grant Date: Pursuant to the BeOne Medicines Ltd. 2016 Share Option and Incentive Plan as amended through the Grant Date (the “Plan”), and this Global Restricted share Unit Award Agreement for Consultants, includi |
|
| May 27, 2025 |
Fourth Amended and Restated 2016 Share Option and Incentive Plan Exhibit 99.2.1 BEONE MEDICINES LTD. FOURTH AMENDED AND RESTATED 2016 SHARE OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the BeOne Medicines Ltd. Fourth Amended and Restated 2016 Share Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consul |
|
| May 27, 2025 |
Articles of Association of the Registrant, as currently in effect Exhibit 3.1 Articles of Association of BeOne Medicines AG (BeOne Medicines Ltd.) (BeOne Medicines SA) Statuten der BeOne Medicines AG / Articles of Association of BeOne Medicines Ltd. 2/43 Abschnitt 1 Firma, Sitz, Zweck und Dauer der Gesellschaft Section 1 Name, Place of Incorporation, Business Purpose, and Duration of the Company Artikel 1 Article 1 Name, Sitz Unter der Firma BeOne Medicines AG ( |
|
| May 27, 2025 |
Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement is entered into by and between BeOne Medicines USA, Inc., a company incorporated under the laws of the State of Delaware (the “Company”), and John V. Oyler (the “Executive”) (the Company and the Executive are each referred to as a “Party” and together as the “Parties”), effective as of the Effective Date (this “Agreeme |
|
| May 27, 2025 |
Fourth Amended and Restated 2016 Share Option and Incentive Plan Exhibit 99.2.1 BEONE MEDICINES LTD. FOURTH AMENDED AND RESTATED 2016 SHARE OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the BeOne Medicines Ltd. Fourth Amended and Restated 2016 Share Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consul |
|
| May 27, 2025 |
As filed with the U.S. Securities and Exchange Commission on May 27, 2025 As filed with the U.S. Securities and Exchange Commission on May 27, 2025 Registration No. 333-209410 Registration No. 333-214064 Registration No. 333-216885 Registration No. 333-223319 Registration No. 333-225543 Registration No. 333-228786 Registration No. 333-241697 Registration No. 333-266639 Registration No. 333-279980 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 PO |
|
| May 27, 2025 |
Exhibit 99.2.4 GLOBAL RESTRICTED Share UNIT AWARD AGREEMENT FOR EMPLOYEES UNDER BeOne Medicines Ltd. 2016 Share OPTION AND INCENTIVE PLAN Name of Grantee: No. of Restricted Share Units: Grant Date: Pursuant to the BeOne Medicines Ltd. 2016 Share Option and Incentive Plan, as amended through the Grant Date (the “Plan”), and this Global Restricted Share Unit Award Agreement for Employees, including |
|
| May 27, 2025 |
Exhibit 99.2.8 GLOBAL NON-QUALIFIED SHARE OPTION AGREEMENT FOR NON-EMPLOYEE Consultants UNDER BeONE Medicines LTD. 2016 SHARE OPTION AND INCENTIVE PLAN Name of Optionee: No. of Option Shares: Ordinary Shares (as defined below) Option Exercise Price per Share: $ [Must be the higher of (a) 1/13 of the closing price of the Company’s ADSs as quoted on the NASDAQ on the date of grant, and (b) 1/13 of |
|
| May 27, 2025 |
Exhibit 99.2.2 CERTAIN INFORMATION (INDICATED BY “[…***…]”) AND SCHEDULES HAVE BEEN EXCLUDED FROM THIS AGREEMENT BECAUSE SUCH INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. GLOBAL performance SHARE UNIT AWARD AGREEMENT UNDER beone medicines Ltd. 2016 Share OPTION AND INCENTIVE PLAN Name of Grantee: Target Number of PSUs Granted: Grant Date: Pursuant |
|
| May 27, 2025 |
2011 Option Plan, as amended and form of option agreement thereunder Exhibit 99.1 BeiGene, LTD 2011 OPTION PLAN (the “Plan”) SECTION 1. GENERAL PURPOSE; DEFINITIONS The purpose of this Plan is to enable persons providing (or expected to provide) services to BeiGene, Ltd. (a Cayman Islands exempted company incorporated with limited liability hereinafter referred to as the “Company”) and its Subsidiaries to acquire ordinary shares in the Company. |
|
| May 27, 2025 |
2011 Option Plan, as amended and form of option agreement thereunder Exhibit 99.1 BeiGene, LTD 2011 OPTION PLAN (the “Plan”) SECTION 1. GENERAL PURPOSE; DEFINITIONS The purpose of this Plan is to enable persons providing (or expected to provide) services to BeiGene, Ltd. (a Cayman Islands exempted company incorporated with limited liability hereinafter referred to as the “Company”) and its Subsidiaries to acquire ordinary shares in the Company. |
|
| May 27, 2025 |
Fifth Amended and Restated 2018 Employee Share Purchase Plan Exhibit 99.3 BEONE MEDICINES LTD. FIFTH AMENDED AND RESTATED 2018 EMPLOYEE SHARE PURCHASE PLAN The purpose of the BeOne Medicines Ltd. Fifth Amended and Restated 2018 Employee Share Purchase Plan (the “Plan”) is to provide the Participants (as defined in Section 1) with opportunities to purchase Shares (either in the form of Ordinary Shares or ADSs). The Plan includes two components: a Code Sectio |
|
| May 27, 2025 |
Form of Indemnification Agreement, entered into between the Company and its directors and officers. Exhibit 10.6 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (this Agreement) is made as of [ ], by and between BeOne Medicines Ltd., a corporation formed and organized under the laws of Switzerland (the Company), and [ ] (the Indemnitee), [a director/an executive officer] of the Company. WHEREAS, the Indemnitee has agreed to serve as [a director/an execu |
|
| May 27, 2025 |
Exhibit 99.2.4 GLOBAL RESTRICTED Share UNIT AWARD AGREEMENT FOR EMPLOYEES UNDER BeOne Medicines Ltd. 2016 Share OPTION AND INCENTIVE PLAN Name of Grantee: No. of Restricted Share Units: Grant Date: Pursuant to the BeOne Medicines Ltd. 2016 Share Option and Incentive Plan, as amended through the Grant Date (the “Plan”), and this Global Restricted Share Unit Award Agreement for Employees, including |
|
| May 27, 2025 |
Exhibit 99.2.6 GLOBAL NON-QUALIFIED Share OPTION AGREEMENT FOR EMPLOYEES UNDER BEONE MEDICINES LTD. 2016 SHARE OPTION AND INCENTIVE PLAN Name of Optionee: No. of Option Shares: Ordinary Shares (as defined below) Option Exercise Price per Share: $ [Must be the higher of (a) 1/13 of the closing price of the Company’s ADSs as quoted on the NASDAQ on the date of grant, and (b) 1/13 of the average clos |
|
| May 27, 2025 |
Exhibit 4.1.3 BeOne Medicines Ltd. Amended and Restated as of May 27, 2025 Citibank, N.A. - ADR Department 388 Greenwich Street New York, New York 10013 Restricted ADSs /Affiliate (CUSIP No.: 07725L136) Ladies and Gentlemen: Reference is made to (i) the Amended and Restated Deposit Agreement, dated as of May 27, 2025, as may be amended and supplemented from time to time (the “Deposit Agreement”), |
|
| May 27, 2025 |
Exhibit 99.2.6 GLOBAL NON-QUALIFIED Share OPTION AGREEMENT FOR EMPLOYEES UNDER BEONE MEDICINES LTD. 2016 SHARE OPTION AND INCENTIVE PLAN Name of Optionee: No. of Option Shares: Ordinary Shares (as defined below) Option Exercise Price per Share: $ [Must be the higher of (a) 1/13 of the closing price of the Company’s ADSs as quoted on the NASDAQ on the date of grant, and (b) 1/13 of the average clos |
|
| May 27, 2025 |
2011 Option Plan, as amended and form of option agreement thereunder Exhibit 99.1 BeiGene, LTD 2011 OPTION PLAN (the “Plan”) SECTION 1. GENERAL PURPOSE; DEFINITIONS The purpose of this Plan is to enable persons providing (or expected to provide) services to BeiGene, Ltd. (a Cayman Islands exempted company incorporated with limited liability hereinafter referred to as the “Company”) and its Subsidiaries to acquire ordinary shares in the Company. |
|
| May 27, 2025 |
Exhibit 99.2.5 GLOBAL RESTRICTED SHARE UNIT AWARD AGREEMENT FOR CONSULTANTS UNDER BEONE MEDICINES LTD. 2016 SHARE OPTION AND INCENTIVE PLAN Name of Grantee: No. of Restricted Share Units: Grant Date: Pursuant to the BeOne Medicines Ltd. 2016 Share Option and Incentive Plan as amended through the Grant Date (the “Plan”), and this Global Restricted share Unit Award Agreement for Consultants, includi |
|
| May 27, 2025 |
Exhibit 99.2.2 CERTAIN INFORMATION (INDICATED BY “[…***…]”) AND SCHEDULES HAVE BEEN EXCLUDED FROM THIS AGREEMENT BECAUSE SUCH INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. GLOBAL performance SHARE UNIT AWARD AGREEMENT UNDER beone medicines Ltd. 2016 Share OPTION AND INCENTIVE PLAN Name of Grantee: Target Number of PSUs Granted: Grant Date: Pursuant |
|
| May 27, 2025 |
Exhibit 99.2.2 CERTAIN INFORMATION (INDICATED BY “[…***…]”) AND SCHEDULES HAVE BEEN EXCLUDED FROM THIS AGREEMENT BECAUSE SUCH INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. GLOBAL performance SHARE UNIT AWARD AGREEMENT UNDER beone medicines Ltd. 2016 Share OPTION AND INCENTIVE PLAN Name of Grantee: Target Number of PSUs Granted: Grant Date: Pursuant |
|
| May 27, 2025 |
Exhibit 99.2.5 GLOBAL RESTRICTED SHARE UNIT AWARD AGREEMENT FOR CONSULTANTS UNDER BEONE MEDICINES LTD. 2016 SHARE OPTION AND INCENTIVE PLAN Name of Grantee: No. of Restricted Share Units: Grant Date: Pursuant to the BeOne Medicines Ltd. 2016 Share Option and Incentive Plan as amended through the Grant Date (the “Plan”), and this Global Restricted share Unit Award Agreement for Consultants, includi |
|
| May 27, 2025 |
Independent Non-Executive Director Compensation Policy, as amended Exhibit 10.10 BEONE MEDICINES LTD. INDEPENDENT NON-EXECUTIVE DIRECTOR COMPENSATION POLICY 1. Purpose The purpose of this independent non-executive director compensation policy (this “Policy”) of BeOne Medicines Ltd. (the “Company”) is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber independent non-executive directors who me |
|
| May 27, 2025 |
2011 Option Plan, as amended and form of option agreement thereunder Exhibit 99.1 BeiGene, LTD 2011 OPTION PLAN (the “Plan”) SECTION 1. GENERAL PURPOSE; DEFINITIONS The purpose of this Plan is to enable persons providing (or expected to provide) services to BeiGene, Ltd. (a Cayman Islands exempted company incorporated with limited liability hereinafter referred to as the “Company”) and its Subsidiaries to acquire ordinary shares in the Company. |
|
| May 27, 2025 |
Exhibit 99.2.8 GLOBAL NON-QUALIFIED SHARE OPTION AGREEMENT FOR NON-EMPLOYEE Consultants UNDER BeONE Medicines LTD. 2016 SHARE OPTION AND INCENTIVE PLAN Name of Optionee: No. of Option Shares: Ordinary Shares (as defined below) Option Exercise Price per Share: $ [Must be the higher of (a) 1/13 of the closing price of the Company’s ADSs as quoted on the NASDAQ on the date of grant, and (b) 1/13 of |
|
| May 27, 2025 |
Exhibit 99.2.3 GLOBAL RESTRICTED Share UNIT AWARD AGREEMENT FOR NON-EMPLOYEE DIRECTORS UNDER beone medicines Ltd. 2016 Share OPTION AND INCENTIVE PLAN Name of Grantee: No. of Restricted Share Units: Grant Date: Pursuant to the BeOne Medicines Ltd. 2016 Share Option and Incentive Plan, as amended through the Grant Date (the “Plan”), and this Global Restricted Share Unit Award Agreement for No |
|
| May 27, 2025 |
Exhibit 99.2.8 GLOBAL NON-QUALIFIED SHARE OPTION AGREEMENT FOR NON-EMPLOYEE Consultants UNDER BeONE Medicines LTD. 2016 SHARE OPTION AND INCENTIVE PLAN Name of Optionee: No. of Option Shares: Ordinary Shares (as defined below) Option Exercise Price per Share: $ [Must be the higher of (a) 1/13 of the closing price of the Company’s ADSs as quoted on the NASDAQ on the date of grant, and (b) 1/13 of |
|
| May 27, 2025 |
As filed with the U.S. Securities and Exchange Commission on May 27, 2025 As filed with the U.S. Securities and Exchange Commission on May 27, 2025 Registration No. 333-209410 Registration No. 333-214064 Registration No. 333-216885 Registration No. 333-223319 Registration No. 333-225543 Registration No. 333-228786 Registration No. 333-241697 Registration No. 333-266639 Registration No. 333-279980 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 PO |
|
| May 27, 2025 |
Fifth Amended and Restated 2018 Employee Share Purchase Plan Exhibit 99.3 BEONE MEDICINES LTD. FIFTH AMENDED AND RESTATED 2018 EMPLOYEE SHARE PURCHASE PLAN The purpose of the BeOne Medicines Ltd. Fifth Amended and Restated 2018 Employee Share Purchase Plan (the “Plan”) is to provide the Participants (as defined in Section 1) with opportunities to purchase Shares (either in the form of Ordinary Shares or ADSs). The Plan includes two components: a Code Sectio |
|
| May 27, 2025 |
Exhibit 99.2.6 GLOBAL NON-QUALIFIED Share OPTION AGREEMENT FOR EMPLOYEES UNDER BEONE MEDICINES LTD. 2016 SHARE OPTION AND INCENTIVE PLAN Name of Optionee: No. of Option Shares: Ordinary Shares (as defined below) Option Exercise Price per Share: $ [Must be the higher of (a) 1/13 of the closing price of the Company’s ADSs as quoted on the NASDAQ on the date of grant, and (b) 1/13 of the average clos |
|
| May 27, 2025 |
Fourth Amended and Restated 2016 Share Option and Incentive Plan Exhibit 99.2.1 BEONE MEDICINES LTD. FOURTH AMENDED AND RESTATED 2016 SHARE OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the BeOne Medicines Ltd. Fourth Amended and Restated 2016 Share Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consul |
|
| May 27, 2025 |
Exhibit 99.2.8 GLOBAL NON-QUALIFIED SHARE OPTION AGREEMENT FOR NON-EMPLOYEE Consultants UNDER BeONE Medicines LTD. 2016 SHARE OPTION AND INCENTIVE PLAN Name of Optionee: No. of Option Shares: Ordinary Shares (as defined below) Option Exercise Price per Share: $ [Must be the higher of (a) 1/13 of the closing price of the Company’s ADSs as quoted on the NASDAQ on the date of grant, and (b) 1/13 of |
|
| May 27, 2025 |
As filed with the U.S. Securities and Exchange Commission on May 27, 2025 As filed with the U.S. Securities and Exchange Commission on May 27, 2025 Registration No. 333-271765 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 to FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BeOne Medicines Ltd. (Exact name of registrant as specified in its charter) Switzerland (State or other jurisdiction of incorpo |
|
| May 27, 2025 |
Exhibit 99.2.5 GLOBAL RESTRICTED SHARE UNIT AWARD AGREEMENT FOR CONSULTANTS UNDER BEONE MEDICINES LTD. 2016 SHARE OPTION AND INCENTIVE PLAN Name of Grantee: No. of Restricted Share Units: Grant Date: Pursuant to the BeOne Medicines Ltd. 2016 Share Option and Incentive Plan as amended through the Grant Date (the “Plan”), and this Global Restricted share Unit Award Agreement for Consultants, includi |
|
| May 27, 2025 |
Exhibit 99.2.2 CERTAIN INFORMATION (INDICATED BY “[…***…]”) AND SCHEDULES HAVE BEEN EXCLUDED FROM THIS AGREEMENT BECAUSE SUCH INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. GLOBAL performance SHARE UNIT AWARD AGREEMENT UNDER beone medicines Ltd. 2016 Share OPTION AND INCENTIVE PLAN Name of Grantee: Target Number of PSUs Granted: Grant Date: Pursuant |
|
| May 27, 2025 |
Exhibit 99.2.2 CERTAIN INFORMATION (INDICATED BY “[…***…]”) AND SCHEDULES HAVE BEEN EXCLUDED FROM THIS AGREEMENT BECAUSE SUCH INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. GLOBAL performance SHARE UNIT AWARD AGREEMENT UNDER beone medicines Ltd. 2016 Share OPTION AND INCENTIVE PLAN Name of Grantee: Target Number of PSUs Granted: Grant Date: Pursuant |
|
| May 27, 2025 |
Exhibit 99.2.4 GLOBAL RESTRICTED Share UNIT AWARD AGREEMENT FOR EMPLOYEES UNDER BeOne Medicines Ltd. 2016 Share OPTION AND INCENTIVE PLAN Name of Grantee: No. of Restricted Share Units: Grant Date: Pursuant to the BeOne Medicines Ltd. 2016 Share Option and Incentive Plan, as amended through the Grant Date (the “Plan”), and this Global Restricted Share Unit Award Agreement for Employees, including |
|
| May 27, 2025 |
Exhibit 99.2.4 GLOBAL RESTRICTED Share UNIT AWARD AGREEMENT FOR EMPLOYEES UNDER BeOne Medicines Ltd. 2016 Share OPTION AND INCENTIVE PLAN Name of Grantee: No. of Restricted Share Units: Grant Date: Pursuant to the BeOne Medicines Ltd. 2016 Share Option and Incentive Plan, as amended through the Grant Date (the “Plan”), and this Global Restricted Share Unit Award Agreement for Employees, including |
|
| May 27, 2025 |
Exhibit 99.2.3 GLOBAL RESTRICTED Share UNIT AWARD AGREEMENT FOR NON-EMPLOYEE DIRECTORS UNDER beone medicines Ltd. 2016 Share OPTION AND INCENTIVE PLAN Name of Grantee: No. of Restricted Share Units: Grant Date: Pursuant to the BeOne Medicines Ltd. 2016 Share Option and Incentive Plan, as amended through the Grant Date (the “Plan”), and this Global Restricted Share Unit Award Agreement for No |
|
| May 27, 2025 |
Fifth Amended and Restated 2018 Employee Share Purchase Plan Exhibit 99.3 BEONE MEDICINES LTD. FIFTH AMENDED AND RESTATED 2018 EMPLOYEE SHARE PURCHASE PLAN The purpose of the BeOne Medicines Ltd. Fifth Amended and Restated 2018 Employee Share Purchase Plan (the “Plan”) is to provide the Participants (as defined in Section 1) with opportunities to purchase Shares (either in the form of Ordinary Shares or ADSs). The Plan includes two components: a Code Sectio |
|
| May 27, 2025 |
Exhibit 99.2.2 CERTAIN INFORMATION (INDICATED BY “[…***…]”) AND SCHEDULES HAVE BEEN EXCLUDED FROM THIS AGREEMENT BECAUSE SUCH INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. GLOBAL performance SHARE UNIT AWARD AGREEMENT UNDER beone medicines Ltd. 2016 Share OPTION AND INCENTIVE PLAN Name of Grantee: Target Number of PSUs Granted: Grant Date: Pursuant |
|
| May 27, 2025 |
Exhibit 99.2.6 GLOBAL NON-QUALIFIED Share OPTION AGREEMENT FOR EMPLOYEES UNDER BEONE MEDICINES LTD. 2016 SHARE OPTION AND INCENTIVE PLAN Name of Optionee: No. of Option Shares: Ordinary Shares (as defined below) Option Exercise Price per Share: $ [Must be the higher of (a) 1/13 of the closing price of the Company’s ADSs as quoted on the NASDAQ on the date of grant, and (b) 1/13 of the average clos |
|
| May 27, 2025 |
Exhibit 99.2.6 GLOBAL NON-QUALIFIED Share OPTION AGREEMENT FOR EMPLOYEES UNDER BEONE MEDICINES LTD. 2016 SHARE OPTION AND INCENTIVE PLAN Name of Optionee: No. of Option Shares: Ordinary Shares (as defined below) Option Exercise Price per Share: $ [Must be the higher of (a) 1/13 of the closing price of the Company’s ADSs as quoted on the NASDAQ on the date of grant, and (b) 1/13 of the average clos |
|
| May 27, 2025 |
As filed with the U.S. Securities and Exchange Commission on May 27, 2025 As filed with the U.S. Securities and Exchange Commission on May 27, 2025 Registration No. 333-209410 Registration No. 333-214064 Registration No. 333-216885 Registration No. 333-223319 Registration No. 333-225543 Registration No. 333-228786 Registration No. 333-241697 Registration No. 333-266639 Registration No. 333-279980 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 PO |
|
| May 27, 2025 |
Exhibit 4.1.4 BeOne Medicines Ltd. Amended and Restated as of May 27, 2025 Citibank, N.A. - ADR Department 388 Greenwich Street New York, New York 10013 Listing of BeOne Medicines Ltd. Shares in Hong Kong Ladies and Gentlemen: Reference is made to (i) the Amended and Restated Deposit Agreement, dated as of May 27, 2025, as may be amended and supplemented from time to time (the “Deposit Agreement”) |
|
| May 27, 2025 |
Exhibit 99.2.3 GLOBAL RESTRICTED Share UNIT AWARD AGREEMENT FOR NON-EMPLOYEE DIRECTORS UNDER beone medicines Ltd. 2016 Share OPTION AND INCENTIVE PLAN Name of Grantee: No. of Restricted Share Units: Grant Date: Pursuant to the BeOne Medicines Ltd. 2016 Share Option and Incentive Plan, as amended through the Grant Date (the “Plan”), and this Global Restricted Share Unit Award Agreement for No |
|
| May 27, 2025 |
Exhibit 99.2.4 GLOBAL RESTRICTED Share UNIT AWARD AGREEMENT FOR EMPLOYEES UNDER BeOne Medicines Ltd. 2016 Share OPTION AND INCENTIVE PLAN Name of Grantee: No. of Restricted Share Units: Grant Date: Pursuant to the BeOne Medicines Ltd. 2016 Share Option and Incentive Plan, as amended through the Grant Date (the “Plan”), and this Global Restricted Share Unit Award Agreement for Employees, including |
|
| May 27, 2025 |
Fourth Amended and Restated 2016 Share Option and Incentive Plan Exhibit 99.2.1 BEONE MEDICINES LTD. FOURTH AMENDED AND RESTATED 2016 SHARE OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the BeOne Medicines Ltd. Fourth Amended and Restated 2016 Share Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consul |
|
| May 27, 2025 |
As filed with the U.S. Securities and Exchange Commission on May 27, 2025 As filed with the U.S. Securities and Exchange Commission on May 27, 2025 Registration No. 333-209410 Registration No. 333-214064 Registration No. 333-216885 Registration No. 333-223319 Registration No. 333-225543 Registration No. 333-228786 Registration No. 333-241697 Registration No. 333-266639 Registration No. 333-279980 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 PO |
|
| May 27, 2025 |
Exhibit 99.2.8 GLOBAL NON-QUALIFIED SHARE OPTION AGREEMENT FOR NON-EMPLOYEE Consultants UNDER BeONE Medicines LTD. 2016 SHARE OPTION AND INCENTIVE PLAN Name of Optionee: No. of Option Shares: Ordinary Shares (as defined below) Option Exercise Price per Share: $ [Must be the higher of (a) 1/13 of the closing price of the Company’s ADSs as quoted on the NASDAQ on the date of grant, and (b) 1/13 of |
|
| May 27, 2025 |
Exhibit 99.2.4 GLOBAL RESTRICTED Share UNIT AWARD AGREEMENT FOR EMPLOYEES UNDER BeOne Medicines Ltd. 2016 Share OPTION AND INCENTIVE PLAN Name of Grantee: No. of Restricted Share Units: Grant Date: Pursuant to the BeOne Medicines Ltd. 2016 Share Option and Incentive Plan, as amended through the Grant Date (the “Plan”), and this Global Restricted Share Unit Award Agreement for Employees, including |
|
| May 27, 2025 |
2011 Option Plan, as amended and form of option agreement thereunder Exhibit 99.1 BeiGene, LTD 2011 OPTION PLAN (the “Plan”) SECTION 1. GENERAL PURPOSE; DEFINITIONS The purpose of this Plan is to enable persons providing (or expected to provide) services to BeiGene, Ltd. (a Cayman Islands exempted company incorporated with limited liability hereinafter referred to as the “Company”) and its Subsidiaries to acquire ordinary shares in the Company. |
|
| May 27, 2025 |
Fifth Amended and Restated 2018 Employee Share Purchase Plan Exhibit 99.3 BEONE MEDICINES LTD. FIFTH AMENDED AND RESTATED 2018 EMPLOYEE SHARE PURCHASE PLAN The purpose of the BeOne Medicines Ltd. Fifth Amended and Restated 2018 Employee Share Purchase Plan (the “Plan”) is to provide the Participants (as defined in Section 1) with opportunities to purchase Shares (either in the form of Ordinary Shares or ADSs). The Plan includes two components: a Code Sectio |
|
| May 27, 2025 |
Form of Indenture for Senior Debt Securities and the related form of senior debt security Exhibit 4.6 BEONE MEDICINES LTD., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [·], 202[·] Senior Debt Securities TABLE OF CONTENTS1 Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms. 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities. 5 Section 2.02 Form of Securities and Trustee’s Certificate |
|
| May 27, 2025 |
Exhibit 99.2.8 GLOBAL NON-QUALIFIED SHARE OPTION AGREEMENT FOR NON-EMPLOYEE Consultants UNDER BeONE Medicines LTD. 2016 SHARE OPTION AND INCENTIVE PLAN Name of Optionee: No. of Option Shares: Ordinary Shares (as defined below) Option Exercise Price per Share: $ [Must be the higher of (a) 1/13 of the closing price of the Company’s ADSs as quoted on the NASDAQ on the date of grant, and (b) 1/13 of |
|
| May 27, 2025 |
Exhibit 99.2.4 GLOBAL RESTRICTED Share UNIT AWARD AGREEMENT FOR EMPLOYEES UNDER BeOne Medicines Ltd. 2016 Share OPTION AND INCENTIVE PLAN Name of Grantee: No. of Restricted Share Units: Grant Date: Pursuant to the BeOne Medicines Ltd. 2016 Share Option and Incentive Plan, as amended through the Grant Date (the “Plan”), and this Global Restricted Share Unit Award Agreement for Employees, including |
|
| May 27, 2025 |
As filed with the U.S. Securities and Exchange Commission on May 27, 2025 As filed with the U.S. Securities and Exchange Commission on May 27, 2025 Registration No. 333-209410 Registration No. 333-214064 Registration No. 333-216885 Registration No. 333-223319 Registration No. 333-225543 Registration No. 333-228786 Registration No. 333-241697 Registration No. 333-266639 Registration No. 333-279980 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 PO |
|
| May 27, 2025 |
Fourth Amended and Restated 2016 Share Option and Incentive Plan Exhibit 99.2.1 BEONE MEDICINES LTD. FOURTH AMENDED AND RESTATED 2016 SHARE OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the BeOne Medicines Ltd. Fourth Amended and Restated 2016 Share Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consul |
|
| May 27, 2025 |
Exhibit 99.2.6 GLOBAL NON-QUALIFIED Share OPTION AGREEMENT FOR EMPLOYEES UNDER BEONE MEDICINES LTD. 2016 SHARE OPTION AND INCENTIVE PLAN Name of Optionee: No. of Option Shares: Ordinary Shares (as defined below) Option Exercise Price per Share: $ [Must be the higher of (a) 1/13 of the closing price of the Company’s ADSs as quoted on the NASDAQ on the date of grant, and (b) 1/13 of the average clos |
|
| May 27, 2025 |
Exhibit 99.2.6 GLOBAL NON-QUALIFIED Share OPTION AGREEMENT FOR EMPLOYEES UNDER BEONE MEDICINES LTD. 2016 SHARE OPTION AND INCENTIVE PLAN Name of Optionee: No. of Option Shares: Ordinary Shares (as defined below) Option Exercise Price per Share: $ [Must be the higher of (a) 1/13 of the closing price of the Company’s ADSs as quoted on the NASDAQ on the date of grant, and (b) 1/13 of the average clos |
|
| May 27, 2025 |
Exhibit 99.2.5 GLOBAL RESTRICTED SHARE UNIT AWARD AGREEMENT FOR CONSULTANTS UNDER BEONE MEDICINES LTD. 2016 SHARE OPTION AND INCENTIVE PLAN Name of Grantee: No. of Restricted Share Units: Grant Date: Pursuant to the BeOne Medicines Ltd. 2016 Share Option and Incentive Plan as amended through the Grant Date (the “Plan”), and this Global Restricted share Unit Award Agreement for Consultants, includi |
|
| May 27, 2025 |
Exhibit 10.4 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement is entered into by and between BeOne Medicines (Shanghai) Co., Ltd., a company incorporated under the laws of the People’s Republic of China (the “Company”), and Lai Wang (the “Executive”) (the Company and the Executive are each referred to as a “Party” and together as the “Parties”), effective as of the Effective Date |
|
| May 27, 2025 |
Exhibit 10.5 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement is entered into by and between BeOne Medicines USA, Inc., a company incorporated under the laws of the State of Delaware (the “Company”), and Chan Lee (the “Executive”) (the Company and the Executive are each referred to as a “Party” and together as the “Parties”), effective as of the Effective Date (this “Agreement”). |
|
| May 27, 2025 |
Exhibit 99.2.5 GLOBAL RESTRICTED SHARE UNIT AWARD AGREEMENT FOR CONSULTANTS UNDER BEONE MEDICINES LTD. 2016 SHARE OPTION AND INCENTIVE PLAN Name of Grantee: No. of Restricted Share Units: Grant Date: Pursuant to the BeOne Medicines Ltd. 2016 Share Option and Incentive Plan as amended through the Grant Date (the “Plan”), and this Global Restricted share Unit Award Agreement for Consultants, includi |
|
| May 27, 2025 |
Exhibit 99.2.5 GLOBAL RESTRICTED SHARE UNIT AWARD AGREEMENT FOR CONSULTANTS UNDER BEONE MEDICINES LTD. 2016 SHARE OPTION AND INCENTIVE PLAN Name of Grantee: No. of Restricted Share Units: Grant Date: Pursuant to the BeOne Medicines Ltd. 2016 Share Option and Incentive Plan as amended through the Grant Date (the “Plan”), and this Global Restricted share Unit Award Agreement for Consultants, includi |
|
| May 27, 2025 |
Exhibit 99.2.2 CERTAIN INFORMATION (INDICATED BY “[…***…]”) AND SCHEDULES HAVE BEEN EXCLUDED FROM THIS AGREEMENT BECAUSE SUCH INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. GLOBAL performance SHARE UNIT AWARD AGREEMENT UNDER beone medicines Ltd. 2016 Share OPTION AND INCENTIVE PLAN Name of Grantee: Target Number of PSUs Granted: Grant Date: Pursuant |
|
| May 21, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 21, 2025 BEIGENE, LTD. (Exact Name of Registrant as Specified in Charter) Cayman Islands 001-37686 98-1209416 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 13, 2025 BEIGENE, LTD. (Exact Name of Registrant as Specified in Charter) Cayman Islands 001-37686 98-1209416 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37686 BEIGENE, |
|
| May 7, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 7, 2025 BEIGENE, LTD. (Exact Name of Registrant as Specified in Charter) Cayman Islands 001-37686 98-1209416 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| May 7, 2025 |
Exhibit 99.1 BeiGene Announces First Quarter 2025 Financial Results and Business Updates •First quarter 2025 total revenues increased 49% to $1.1 billion with BRUKINSA® (zanubrutinib) global sales increasing 62% to $792 million on strong demand growth versus first quarter 2024 •Achieved GAAP profitability and significantly improved operating cash flow •Advanced late-stage hematology and solid tumo |
|
| May 1, 2025 |
Exhibit (b)(iii) BeOne Medicines Ltd. Amended and Restated as of [●], 2025 Citibank, N.A. – ADR Department 388 Greenwich Street New York, New York 10013 Attention: Account Management BeOne Medicines Ltd. (CUSIP No.: 07725L987) Dear Sirs: Reference is hereby made to (i) the Amended and Restated Deposit Agreement, dated as of [●], 2025, as may be amended and supplemented from time to time (the “Depo |
|
| May 1, 2025 |
As filed with the Securities and Exchange Commission on May 1, 2025 Registration No. |
|
| May 1, 2025 |
Exhibit (b)(ii) BeOne Medicines Ltd. Amended and Restated as of [●], 2025 Citibank, N.A. - ADR Department 388 Greenwich Street New York, New York 10013 Listing of BeOne Medicines Ltd. Shares in Hong Kong Ladies and Gentlemen: Reference is made to (i) the Amended and Restated Deposit Agreement, dated as of [●], 2025, as may be amended and supplemented from time to time (the “Deposit Agreement”), by |
|
| May 1, 2025 |
Exhibit (b)(i) BeiGene, Ltd. Amended and Restated as of [●], 2025 Citibank, N.A. - ADR Department 388 Greenwich Street New York, New York 10013 Restricted ADSs /Affiliate (CUSIP No.: 07725L136) Ladies and Gentlemen: Reference is made to (i) the Amended and Restated Deposit Agreement, dated as of [●], 2025, as may be amended and supplemented from time to time (the “Deposit Agreement”), by and among |
|
| May 1, 2025 |
Exhibit (a)(i) AMENDED AND RESTATED DEPOSIT AGREEMENT by and among BeOne Medicines Ltd. |
|
| April 29, 2025 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): April 29, 2025 BEIGENE, LTD. (Exact Name of Registrant as Specified in Charter) Cayman Islands 001-37686 98-1209416 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| April 28, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): April 28, 2025 BEIGENE, LTD. (Exact Name of Registrant as Specified in Charter) Cayman Islands 001-37686 98-1209416 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| April 28, 2025 |
Exhibit 99.1 Financial Information On April 28, 2025, BeiGene, Ltd. (the “Company”) filed its 2024 Annual Report (the “STAR Annual Report”) with the Science and Technology Innovation Board (the “STAR Market”) of the Shanghai Stock Exchange, which was prepared in accordance with the listing rules of the STAR Market and the applicable securities laws and regulations of the Peoples’ Republic of China |
|
| April 28, 2025 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): April 28, 2025 BEIGENE, LTD. (Exact Name of Registrant as Specified in Charter) Cayman Islands 001-37686 98-1209416 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| April 24, 2025 |
Exhibit (b)(v) BeiGene, Ltd. As of August 2, 2018 Citibank, N.A. - ADR Department 388 Greenwich Street New York, New York 10013 Listing of Beigene Shares in Hong Kong Ladies and Gentlemen: Reference is made to the Deposit Agreement, dated as of February 5, 2016, as amended as of April 11, 2016, and as further amended and supplemented from time to time (the “Deposit Agreement”), by and among BeiGen |
|
| April 24, 2025 |
Exhibit (b)(i) BeiGene, Ltd. Amended and Restated as of [●], 2025 Citibank, N.A. - ADR Department 388 Greenwich Street New York, New York 10013 Restricted ADSs /Affiliate (CUSIP No.: 07725L136) Ladies and Gentlemen: Reference is made to (i) the Amended and Restated Deposit Agreement, dated as of [●], 2025, as may be amended and supplemented from time to time (the “Deposit Agreement”), by and among |
|
| April 24, 2025 |
Exhibit (a)(ii) BEIGENE, LTD. AND CITIBANK, N.A., As Depositary, AND ALL HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES OUTSTANDING UNDER THE TERMS OF THE DEPOSIT AGREEMENT, DATED AS OF FEBRUARY 5, 2016 Amendment No. 1 to Deposit Agreement Dated as of April 11, 2016 Table of Contents Page ARTICLE I 2 DEFINITIONS 2 SECTION 1.01. Definitions. 2 SECTION 1.02. Effective Date 2 ARTICLE II |
|
| April 24, 2025 |
Exhibit (b)(iv) December 30, 2019 Citibank, N.A., as Depositary ADR Department 388 Greenwich Street, 14th Floor New York, New York 10013 Attention: Account Management BeiGene, Ltd. (Cusip # 07725L987) Dear Sirs: Reference is hereby made to (i) the Deposit Agreement, dated as of February 5, 2016, as amended and supplemented from time to time (the “Deposit Agreement”), by and among BeiGene, Ltd. (th |
|
| April 24, 2025 |
Exhibit (b)(ii) BeOne Medicines Ltd. Amended and Restated as of [●], 2025 Citibank, N.A. - ADR Department 388 Greenwich Street New York, New York 10013 Listing of BeOne Medicines Ltd. Shares in Hong Kong Ladies and Gentlemen: Reference is made to (i) the Amended and Restated Deposit Agreement, dated as of [●], 2025, as may be amended and supplemented from time to time (the “Deposit Agreement”), by |
|
| April 24, 2025 |
Exhibit (b)(vi) BeiGene, Ltd. As of July 11, 2016 Citibank, N.A. - ADR Department 388 Greenwich Street New York, New York 10013 Restricted ADSs /Affiliate (Cusip # 07725L136) Ladies and Gentlemen: Reference is made to the Deposit Agreement, dated as of February 5, 2016, as amended and supplemented from time to time (the “Deposit Agreement”), by and among BeiGene, Ltd., a company organized under th |
|
| April 24, 2025 |
As filed with the Securities and Exchange Commission on April 24, 2025 Registration No. |
|
| April 24, 2025 |
Exhibit (d) April 24, 2025 Citibank, N.A. – ADR Department 388 Greenwich Street New York, New York 10013 Ladies and Gentlemen: We refer to the Registration Statement on Form F-6 (the “Registration Statement”) to be filed with the Securities and Exchange Commission (the “SEC”) by the legal entity created by the Deposit Agreement (as hereinafter defined) for the purpose of registering under the Unit |
|
| April 24, 2025 |
Exhibit (b)(iii) BeOne Medicines Ltd. Amended and Restated as of [●], 2025 Citibank, N.A. – ADR Department 388 Greenwich Street New York, New York 10013 Attention: Account Management BeOne Medicines Ltd. (CUSIP No.: 07725L987) Dear Sirs: Reference is hereby made to (i) the Amended and Restated Deposit Agreement, dated as of [●], 2025, as may be amended and supplemented from time to time (the “Depo |
|
| April 24, 2025 |
Exhibit (a)(i) AMENDED AND RESTATED DEPOSIT AGREEMENT by and among BeOne Medicines Ltd. |
|
| April 7, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statements ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1 |
|
| April 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| March 27, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statements ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1 |
|
| March 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| March 10, 2025 |
TABLE OF CONTENTS Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-281324 PROXY STATEMENT FOR EXTRAORDINARY GENERAL MEETING OF BEIGENE, LTD. PROSPECTUS FOR ORDINARY SHARES CONTINUATION TO SWITZERLAND BeiGene, Ltd. (the “Company” or “we”) is an exempted company incorporated in the Cayman Islands with limited liability. We are proposing to change our jurisdiction of incorporation fr |
|
| March 6, 2025 |
March 6, 2025 By EDGAR Submission U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F. Street, N.E. Washington, D.C. 20549 Attention: Ms. Doris Stacey Gama and Mr. Chris Edwards Re: BeiGene, Ltd. Acceleration Request for Registration Statement on Form S-4 File No. 333-281324 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 193 |
|
| February 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission f |
|
| February 28, 2025 |
Calculation of Filing Fee Tables S-4 BeiGene, Ltd. Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing |
|
| February 28, 2025 |
As filed with the U.S. Securities and Exchange Commission on February 27, 2025 TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on February 27, 2025 Registration No. 333-281324 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BEIGENE, LTD. (Exact name of Registrant as specified in its charter) Cayman Islands* 2834 98-1209416 (State or other ju |
|
| February 28, 2025 |
Exhibit 24.2 POWER OF ATTORNEY KNOW ALL BY THESE PRESENT, that the individual whose signature appears below hereby constitutes and appoints John V. Oyler, Aaron Rosenberg and Chan Lee, each acting together or alone, as such person’s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person’s name, place and stead, in any and all c |
|
| February 27, 2025 |
Exhibit 4.5 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of our share capital is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to our seventh amended and restated memorandum and articles of association (as amended or amended and restated, “our articles”), whi |
|
| February 27, 2025 |
List of Subsidiaries of the Registrant Exhibit 21 Subsidiaries Name of Subsidiary Jurisdiction of Incorporation or Organization Percentage of Ownership by the Registrant BeiGene 101 Cayman Islands 100 % BeiGene Argentina S. |
|
| February 27, 2025 |
Exhibit 10.23 Second Amendment to the Settlement and Termination Agreement This Second Amendment to the Settlement and Termination Agreement (this “Second Amendment”) is entered into as of December 4, 2024 (the “Second Amendment Effective Date”) by and among Bristol- Myers Squibb Company, a Delaware corporation (“BMS”), Celgene Corporation, a Delaware corporation (“Celgene Corporation”), Celgene S |
|
| February 27, 2025 |
February 27, 2025 By EDGAR Submission U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F. Street, N.E. Washington, D.C. 20549 Attention: Ms. Doris Stacey Gama and Mr. Chris Edwards Re: BeiGene, Ltd. Amendment No. 1 to Registration Statement on Form S-4 Filed January 21, 2025 File No. 333-281324 Dear Ms. Doris Stacey Gama and Mr. Chris Edwards: Bei |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): February 27, 2025 BEIGENE, LTD. (Exact Name of Registrant as Specified in Charter) Cayman Islands 001-37686 98-1209416 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| February 27, 2025 |
Special Trading Procedures for Insiders Exhibit 19.2 BEIGENE, LTD. SPECIAL TRADING PROCEDURES FOR INSIDERS To comply with federal and state securities laws of the United States, the Hong Kong Model Code for Securities Dealings by Directors of Listed Issuers (the “Model Code”) set out in Appendix 10 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and certain provisions of the Securities and Fut |
|
| February 27, 2025 |
Disclosure Regarding Foreign Jurisdictions that Prevent Inspections Exhibit 99.1 DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS In March 2022, the U.S. Securities and Exchange Commission (“SEC”) added BeiGene, Ltd. (the “Company”) to its conclusive list of issuers identified under the Holdings Foreign Companies Accountable Act (“HFCAA”) following the filing of our annual report on Form 10-K with the SEC, which annual report was audited by Erns |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37 |
|
| February 27, 2025 |
Exhibit 99.1 BeiGene Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates •Total global revenues of $1.1 billion and $3.8 billion for the fourth quarter and full year, increases of 78% and 55%, respectively; narrowed GAAP operating loss and achieved full-year positive non-GAAP operating income •Global BRUKINSA revenues of $828 million and $2.6 billion for the fourth q |
|
| January 21, 2025 |
Calculation of Filing Fee Tables S-4 BeiGene, Ltd. Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing |
|
| January 21, 2025 |
Proposed Form of Organizational Regulations of the Registrant Exhibit 3.2 Organizational Regulations dated as of [], 2025 of BeOne Medicines Ltd. a Swiss corporation with its registered office in Basel, Canton of Basel-Stadt, Switzerland 1. Scope and Basis (a) These Organizational Regulations (the Regulations) are enacted by the board of directors (the Board) of BeOne Medicines Ltd. (the Company) pursuant to article 716b of the Swiss Code of Obligations, dat |
|
| January 21, 2025 |
Consent of Goodwin Procter LLP (included in Exhibit 8.3) Exhibit 8.3 Goodwin Procter LLP 100 Northern Avenue Boston, MA 02210 goodwinlaw.com +1 617 570 1000 January 21, 2025 BeiGene, Ltd. c/o Mourant Governance Services (Cayman) Limited 94 Solaris Avenue, Camana Bay Grand Cayman Cayman Islands KY1-1108 Ladies and Gentlemen: We have acted as counsel to BeiGene, Ltd., an exempted company incorporated in the Cayman Islands with limited liability (the “Comp |
|
| January 21, 2025 |
As filed with the U.S. Securities and Exchange Commission on January 21, 2025 TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on January 21, 2025 Registration No. 333-281324 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BEIGENE, LTD. (Exact name of Registrant as specified in its charter) Cayman Islands* 2834 98-1209416 (State or other jur |
|
| January 21, 2025 |
Exhibit 99.1 PRELIMINARY COPY – SUBJECT TO COMPLETION Cayman Islands Company No. 247127 BEIGENE, LTD. 百濟神州有限公司 (Stock Code: NASDAQ: ONC | HKEX: 06160 | SSE: 688235) (the “Company”) FORM OF PROXY I/We Please Print Name(s) of Please Print Address(es) being (a) shareholder(s) of the Company, hereby appoint the Chairman of the meeting or of Please Print Name Please Print Address as my/our proxy to v |
|
| January 21, 2025 |
January 21, 2025 By EDGAR Submission U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F. Street, N.E. Washington, D.C. 20549 Attention: Ms. Doris Stacey Gama and Mr. Chris Edwards Re: BeiGene, Ltd. Registration Statement on Form S-4 Filed August 7, 2024 File No. 333-281324 Dear Ms. Doris Stacey Gama and Mr. Chris Edwards: BeiGene, Ltd. (the “Compa |
|
| January 21, 2025 |
Exhibit 23.7 FANGDA PARTNERS http://www.fangdalaw.com 中国上海市石门一路288号 电子邮件 E-mail: [email protected] 兴业太古汇香港兴业中心二座24楼 电 话 Tel.: +86-21-2208 1166 邮政编码：200041 传 真 Fax.: +86-21-5298 5599 24/F, HKRI Centre Two HKRI Taikoo Hui 288 Shi Men Yi Road Shanghai, PRC 200041 To: BeiGene, Ltd. January 21, 2025 Re: Consent of Fangda Partners Dear Sirs, We hereby consent to the reference of our name under t |
|
| January 21, 2025 |
List of Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries Name of Subsidiary Jurisdiction of Incorporation or Organization Percentage of Ownership by the Registrant BeiGene 101 Cayman Islands 100 % BeiGene Argentina S.R.L. Argentina 100 % BeiGene AUS Pty Ltd Australia 100 % BeiGene Austria GmbH Austria 100 % BeiGene (Beijing) Co., Ltd. People’s Republic of China 100 % BeiGene Belgium SRL Belgium 100 % BeiGene Biologics Co., Ltd. |
|
| January 21, 2025 |
Exhibit 4.2.1 AMENDED AND RESTATED DEPOSIT AGREEMENT by and among BeOne Medicines Ltd. and CITIBANK, N.A., as Depositary, and ALL HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES ISSUED HEREUNDER Dated as of [·] TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 Section 1.1. “ADS Record Date” 1 Section 1.2. “Affiliate” 1 Section 1.3. “American Depositary Receipt(s)”, “ADR(s)” and “Receipt(s |
|
| January 13, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): January 13, 2025 BEIGENE, LTD. (Exact Name of Registrant as Specified in Charter) Cayman Islands 001-37686 98-1209416 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| January 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37 |
|
| December 23, 2024 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): December 23, 2024 BEIGENE, LTD. (Exact Name of Registrant as Specified in Charter) Cayman Islands 001-37686 98-1209416 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| December 10, 2024 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. |
|
| December 10, 2024 |
Exhibit 10.1 [This English version is for reference only. In case any discrepancy exists between the Chinese and English version, the Chinese version shall prevail] Important Note: Dear customers, in order to protect your rights and interests, please read the full content of this Agreement carefully before your execution, especially the articles in bold. In case of any doubt, please ask us for exp |
|
| December 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): December 9, 2024 BEIGENE, LTD. (Exact Name of Registrant as Specified in Charter) Cayman Islands 001-37686 98-1209416 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| December 4, 2024 |
SC 13D/A 1 p24-3466sc13da.htm BEIGENE, LTD. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* BeiGene, Ltd. (Name of Issuer) Ordinary shares, par value $0.0001 per share (Title of Class of Securities) 07725L102 (CUSIP Number) Richard A. Hornung HHLR Advisors, Ltd. Office #122, Windward 3 Building, Regatta Office Pa |
|
| November 19, 2024 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): November 14, 2024 BEIGENE, LTD. (Exact Name of Registrant as Specified in Charter) Cayman Islands 001-37686 98-1209416 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 14, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): November 14, 2024 BEIGENE, LTD. (Exact Name of Registrant as Specified in Charter) Cayman Islands 001-37686 98-1209416 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 12, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): November 12, 2024 BEIGENE, LTD. (Exact Name of Registrant as Specified in Charter) Cayman Islands 001-37686 98-1209416 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 12, 2024 |
Exhibit 99.1 BeiGene Announces Third Quarter 2024 Financial Results and Corporate Updates •Continued financial progress with $1 billion in quarterly total revenue, reduced GAAP loss and second consecutive quarter of positive non-GAAP operating income •Strengthened franchise leadership in chronic lymphocytic leukemia (CLL) with foundational therapy BRUKINSA, global revenue of $690 million, rapidly |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37686 BEIGE |
|
| October 31, 2024 |
LPTX / Leap Therapeutics, Inc. / Beigene, Ltd. - SC 13D/A Activist Investment United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Information to be Included in Statements Filed Pursuant to 240.13d-1(a) and Amendments Thereto Filed Pursuant to 240.13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 2)* Leap Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities |
|
| October 28, 2024 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): October 25, 2024 BEIGENE, LTD. (Exact Name of Registrant as Specified in Charter) Cayman Islands 001-37686 98-1209416 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| October 24, 2024 |
October 24, 2024 By EDGAR Submission U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F. Street, N.E. Washington, D.C. 20549 Attention: Ms. Doris Stacey Gama and Mr. Chris Edwards Re: BeiGene, Ltd. Registration Statement on Form S-4 Filed August 7, 2024 File No. 333-281324 Dear Ms. Doris Stacey Gama and Mr. Chris Edwards: BeiGene, Ltd. (the “Compa |
|
| September 30, 2024 |
Exhibit 99.1 Item 1A. Risk Factors The following section includes material factors that we believe may adversely affect our business and operations. You should carefully consider the risks and uncertainties described below and all information contained in our most recently filed Quarterly Report on Form 10-Q (the “Quarterly Report”), including our financial statements and the related notes and “Pa |
|
| September 30, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): September 30, 2024 BEIGENE, LTD. (Exact Name of Registrant as Specified in Charter) Cayman Islands 001-37686 98-1209416 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| September 26, 2024 |
Global Oncology Innovator BeiGene Appoints Shalini Sharp to Board of Directors Exhibit 99.1 Global Oncology Innovator BeiGene Appoints Shalini Sharp to Board of Directors SAN MATEO, Calif. – (BUSINESS WIRE) – BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Shalini Sharp to its Board of Directors and as a member of the Board’s Audit Committee, effective September 27, 2024. “We are fortunate to welcome Shali |
|
| September 26, 2024 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): September 25, 2024 BEIGENE, LTD. (Exact Name of Registrant as Specified in Charter) Cayman Islands 001-37686 98-1209416 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| August 29, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 29, 2024 BEIGENE, LTD. (Exact Name of Registrant as Specified in Charter) Cayman Islands 001-37686 98-1209416 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| August 29, 2024 |
Exhibit 99.1 Financial Information On August 29, 2024, BeiGene, Ltd. (the “Company”) filed its 2024 Interim Report for the six months ended June 30, 2024 (the “STAR Interim Report”) with the Science and Technology Innovation Board (the “STAR Market”) of the Shanghai Stock Exchange, which was prepared in accordance with the listing rules of the STAR Market and the applicable securities laws and reg |
|
| August 21, 2024 |
August 21, 2024 By EDGAR Submission U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F. Street, N.E. Washington, D.C. 20549 Attention: Ms. Doris Stacey Gama and Mr. Chris Edwards Re: BeiGene, Ltd. Form 10-K for the Fiscal Year Ended December 31, 2023 Filed February 26, 2024 File No. 001-37686 Dear Ms. Gama and Mr. Edwards: BeiGene, Ltd. (the “Comp |
|
| August 7, 2024 |
Exhibit 10.4 SEPARATION AND TRANSITION AGREEMENT This Separation and Transition Agreement (“Agreement”) is made and entered into between BeiGene USA, Inc. (“BeiGene” or the “Company”), an indirect, wholly-owned subsidiary of BeiGene, Ltd., on behalf of itself and for the benefit of its parent corporation, affiliates, subsidiaries, divisions, predecessors, and each of their past and present officer |
|
| August 7, 2024 |
Exhibit 10.5 GLOBAL PERFORMANCE SHARE UNIT AWARD AGREEMENT UNDER BEIGENE, LTD. 2016 SHARE OPTION AND INCENTIVE PLAN Name of Grantee: Target Number of PSUs Granted: Grant Date: Pursuant to the BeiGene, Ltd. 2016 Share Option and Incentive Plan, as amended through the Grant Date (the “Plan”), and this Global Performance Share Unit Award Agreement, including the additional performance-based vesting c |
|
| August 7, 2024 |
Offer Letter, effective July 22, 2024, by and between the Registrant and Aaron Rosenberg Exhibit 10.3 June 17, 2024 Aaron Rosenberg via: [email protected] Dear Aaron: This letter agreement (this “Agreement”) shall confirm the terms and conditions of your at-will employment with BeiGene USA, Inc. (“BeiGene” or the “Company”), a subsidiary of BeiGene, Ltd. We are excited about you joining our team and look forward to the addition of your professionalism and experience to help t |
|
| August 7, 2024 |
Exhibit 10.9 GLOBAL NON-QUALIFIED SHARE OPTION AGREEMENT FOR CONSULTANTS UNDER BEIGENE, LTD. 2016 SHARE OPTION AND INCENTIVE PLAN Name of Optionee: No. of Option Shares: Ordinary Shares (as defined below) Option Exercise Price per Share: $ [Must be the higher of (a) 1/13 of the closing price of the Company’s ADSs as quoted on the NASDAQ on the date of grant, and (b) 1/13 of the average closing pri |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37686 BEIGENE, L |
|
| August 7, 2024 |
Exhibit 10.6 GLOBAL RESTRICTED SHARE UNIT AWARD AGREEMENT FOR EMPLOYEES UNDER BEIGENE, LTD. 2016 SHARE OPTION AND INCENTIVE PLAN Name of Grantee: No. of Restricted Share Units: Grant Date: Pursuant to the BeiGene, Ltd. 2016 Share Option and Incentive Plan, as amended through the Grant Date (the “Plan”), and this Global Restricted Share Unit Award Agreement for Employees, including any additional t |
|
| August 7, 2024 |
Exhibit 10.7 GLOBAL RESTRICTED SHARE UNIT AWARD AGREEMENT FOR CONSULTANTS UNDER BEIGENE, LTD. 2016 SHARE OPTION AND INCENTIVE PLAN Name of Grantee: No. of Restricted Share Units: Grant Date: Pursuant to the BeiGene, Ltd. 2016 Share Option and Incentive Plan as amended through the Grant Date (the “Plan”), and this Global Restricted share Unit Award Agreement for Consultants, including any additiona |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 7, 2024 BEIGENE, LTD. (Exact Name of Registrant as Specified in Charter) Cayman Islands 001-37686 98-1209416 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| August 7, 2024 |
Exhibit 99.1 BeiGene Enters Next Phase of Global Growth with Announcement of Second Quarter 2024 Financial Results and Corporate Updates •Generated total revenues of $929 million, an increase of 56% from the prior-year period; reduced GAAP operating loss and achieved non-GAAP operating income •Strengthened hematology leadership with global BRUKINSA revenues of $637 million, an increase of 107% fro |
|
| August 7, 2024 |
Exhibit 10.8 GLOBAL NON-QUALIFIED SHARE OPTION AGREEMENT FOR EMPLOYEES UNDER BEIGENE, LTD. 2016 SHARE OPTION AND INCENTIVE PLAN Name of Optionee: No. of Option Shares: Ordinary Shares (as defined below) Option Exercise Price per Share: $ [Must be the higher of (a) 1/13 of the closing price of the Company’s ADSs as quoted on the NASDAQ on the date of grant, and (b) 1/13 of the average closing price |
|
| August 7, 2024 |
Calculation of Filing Fee Tables S-4 BeiGene, Ltd. Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing |
|
| August 7, 2024 |
Exhibit 99.1 PRELIMINARY COPY – SUBJECT TO COMPLETION Cayman Islands Company No. 247127 BEIGENE, LTD. 百濟神州有限公司 (Stock Code: NASDAQ: BGNE | HKEX: 06160 | SSE: 688235) (the “Company”) FORM OF PROXY I/We Please Print Name(s) of Please Print Address(es) being (a) shareholder(s) of the Company, hereby appoint the Chairman of the meeting or of Please Print Name Please Print Address as my/our proxy to |
|
| August 7, 2024 |
Proposed Form of Organizational Regulations of the Registrant Exhibit 3.2 Organizational Regulations dated as of [], 2024 of BeiGene, Ltd. a Swiss corporation with its registered office in Basel, Canton of Basel-Stadt, Switzerland 1. Scope and Basis (a) These Organizational Regulations (the Regulations) are enacted by the board of directors (the Board) of BeiGene, Ltd. (the Company) pursuant to article 716b of the Swiss Code of Obligations, dated as of March |
|
| August 7, 2024 |
List of Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries Name of Subsidiary Jurisdiction of Incorporation or Organization Percentage of Ownership by the Registrant BeiGene 101 Cayman Islands 100 % BeiGene Argentina S.R.L. Argentina 100 % BeiGene AUS Pty Ltd Australia 100 % BeiGene Austria GmbH Austria 100 % BeiGene (Beijing) Co., Ltd. People’s Republic of China 100 % BeiGene Belgium SRL Belgium 100 % BeiGene Biologics Co., Ltd. |
|
| August 7, 2024 |
As filed with the U.S. Securities and Exchange Commission on August 7, 2024 TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on August 7, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BEIGENE, LTD. (Exact name of Registrant as specified in its charter) Cayman Islands* 2834 98-1209416 (State or other jurisdiction of incor |
|
| July 31, 2024 |
July 31, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, DC 20549 Attention: Ms. Doris Stacey Gama Mr. Chris Edwards Re: SEC Comment Letter dated July 25, 2024 BeiGene, Ltd. Form 10-K for the Fiscal Year Ended December 31, 2023 Filed February 26, 2024 File No. 001-37686 Dear Ms. Gama and Mr. Edwards, BeiG |
|
| July 18, 2024 |
BeiGene Announces Appointment of Aaron Rosenberg as Chief Financial Officer Exhibit 99.1 BeiGene Announces Appointment of Aaron Rosenberg as Chief Financial Officer SAN MATEO, Calif. – (BUSINESS WIRE) – BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Aaron Rosenberg as Chief Financial Officer, effective July 22. Mr. Rosenberg will succeed Julia Wang, who is departing to pursue external opportunities and |
|
| July 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): July 17, 2024 BEIGENE, LTD. (Exact Name of Registrant as Specified in Charter) Cayman Islands 001-37686 98-1209416 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| June 5, 2024 |
As filed with the Securities and Exchange Commission on June 5, 2024 As filed with the Securities and Exchange Commission on June 5, 2024 Registration No. |
|
| June 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): June 5, 2024 BEIGENE, LTD. (Exact Name of Registrant as Specified in Charter) Cayman Islands 001-37686 98-1209416 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| June 5, 2024 |
Fourth Amended and Restated 2018 Employee Share Purchase Plan Exhibit 10.2 BEIGENE, LTD. FOURTH AMENDED AND RESTATED 2018 EMPLOYEE SHARE PURCHASE PLAN The purpose of the BeiGene, Ltd. Fourth Amended and Restated 2018 Employee Share Purchase Plan (the “Plan”) is to provide the Participants (as defined in Section 1) with opportunities to purchase Shares (either in the form of Ordinary Shares or ADSs). The Plan includes two components: a Code Section 423 compon |
|
| June 5, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) BEIGENE, LTD. (Exact name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(2) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary Shares, par value $0.0001 |
|
| June 5, 2024 |
Third Amended and Restated 2016 Share Option and Incentive Plan Exhibit 10.1 BEIGENE, LTD. THIRD AMENDED AND RESTATED 2016 SHARE OPTION AND INCENTIVE PLAN SECTION 1.GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the BeiGene, Ltd. Third Amended and Restated 2016 Share Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of BeiGene, Ltd. (the “ |
|
| May 8, 2024 |
Consulting Agreement, dated January 23, 2024, by and between the Registrant and Thomas Malley Exhibit 10.2 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (the “Consulting Agreement”), effective as of January 23, 2024, is entered into by BeiGene, Ltd., a Cayman Islands exempted company (the “Company”), and Thomas Malley (the “Consultant”). WHEREAS, the Company desires to retain the services of the Consultant and the Consultant desires to perform certain services for the Company on a consult |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37686 BEIGENE, |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 8, 2024 BEIGENE, LTD. (Exact Name of Registrant as Specified in Charter) Cayman Islands 001-37686 98-1209416 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| May 8, 2024 |
Exhibit 99.1 BeiGene Reports First Quarter 2024 Financial Results and Business Updates •Total revenues of $752 million in the first quarter, including product revenue of $747 million, an 82% increase from the prior-year period •BRUKINSA revenue of $489 million, driven by growth in the U.S. and Europe of 153% and 243%, respectively, from the prior-year period; with recent fifth FDA approval, BRUKIN |
|
| April 26, 2024 |
Exhibit 99.1 Financial Information On April 26, 2024, BeiGene, Ltd. (the “Company”) filed its 2023 Annual Report (the “STAR Annual Report”) with the Science and Technology Innovation Board (the “STAR Market”) of the Shanghai Stock Exchange, which was prepared in accordance with the listing rules of the STAR Market and the applicable securities laws and regulations of the Peoples’ Republic of China |
|
| April 26, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statements ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1 |
|
| April 26, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): April 26, 2024 BEIGENE, LTD. (Exact Name of Registrant as Specified in Charter) Cayman Islands 001-37686 98-1209416 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| April 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): April 23, 2024 BEIGENE, LTD. (Exact Name of Registrant as Specified in Charter) Cayman Islands 001-37686 98-1209416 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| April 23, 2024 |
Exhibit 99.1 BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer Comprehensive development program, including three Phase 3 clinical trials, demonstrated benefit of tislelizumab for patients with treatment-naïve and relapsed NSCLC Decision represents tislelizumab’s second approval in the region BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. - |
|
| April 15, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statements ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1 |
|
| March 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 19, 2024 BEIGENE, LTD. (Exact Name of Registrant as Specified in Charter) Cayman Islands 001-37686 98-1209416 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| March 20, 2024 |
Independent Director Compensation Policy, as amended Exhibit 10.1 BEIGENE, LTD. INDEPENDENT DIRECTOR COMPENSATION POLICY The purpose of this Independent Director Compensation Policy (this “Policy”) of BeiGene, Ltd. (the “Company”) is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who meet the general independence requirements under NASDAQ Rule 5605(a)(2) and Rule 3 |
|
| March 15, 2024 |
Exhibit 99.1 BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy Results from the global, Phase 3 RATIONALE 302 trial showed TEVIMBRA prolonged the survival of patients who received prior systemic treatment compared to chemotherapy Approval represents the first indication in the U.S. for TEVIMBRA BASEL, |
|
| March 15, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 14, 2024 BEIGENE, LTD. (Exact Name of Registrant as Specified in Charter) Cayman Islands 001-37686 98-1209416 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| March 8, 2024 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 8, 2024 BEIGENE, LTD. (Exact Name of Registrant as Specified in Charter) Cayman Islands 001-37686 98-1209416 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| February 26, 2024 |
Exhibit 4.6 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of our share capital is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to our seventh amended and restated memorandum and articles of association (as amended or amended and restated, “our articles”), whi |
|
| February 26, 2024 |
Disclosure Regarding Foreign Jurisdictions that Prevent Inspections Exhibit 99.1 DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS In March 2022, the U.S. Securities and Exchange Commission (“SEC”) added BeiGene, Ltd. (the “Company”) to its conclusive list of issuers identified under the Holdings Foreign Companies Accountable Act (“HFCAA”) following the filing of our annual report on Form 10-K with the SEC, which annual report was audited by Erns |
|
| February 26, 2024 |
Exhibit 97 BEIGENE, LTD. COMPENSATION RECOVERY POLICY Adopted as of November 21, 2023 BeiGene, Ltd., an exempted company with limited liability incorporated in the Cayman Islands (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1. Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded |
|
| February 26, 2024 |
List of Subsidiaries of the Registrant Exhibit 21 Subsidiaries Name of Subsidiary Jurisdiction of Incorporation or Organization Percentage of Ownership by the Registrant B10 Health Technologies Private Limited India 100 % BeiGene 101 Cayman Islands 100 % BeiGene Argentina S. |
|
| February 26, 2024 |
Exhibit 10.21 CERTAIN INFORMATION (INDICATED BY “[…***…]”) HAS BEEN EXCLUDED FROM THIS AGREEMENT BECAUSE SUCH INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. First Amendment to the Settlement and Termination Agreement This First Amendment to the Settlement and Termination Agreement (this “First Amendment”) is entered into as of January 10, 2024 (the “ |
|
| February 26, 2024 |
Exhibit 99.1 BeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates •Continued rapid global growth with record total revenues of $634 million in fourth quarter and $2.5 billion in full-year 2023, increases of 67% and 74% from the prior-year periods •Strengthened leadership in hematology with global BRUKINSA® (zanubrutinib) sales of $413 million and $1.3 billion fo |
|
| February 26, 2024 |
Exhibit 19.1 BEIGENE, LTD. INSIDER TRADING POLICY This Insider Trading Policy of BeiGene, Ltd. and its subsidiaries (collectively, the “Company”) sets forth the Company’s policies for trading in the Company’s securities. Insider trading occurs when a person takes information about the Company, its customers, suppliers, or others with which the Company does (or may do) business that the public does |
|
| February 26, 2024 |
Consulting Agreement, dated December 7, 2023, by and between the Registrant and Xiaodong Wang Exhibit 10.16 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (the “Consulting Agreement”), dated as of December 7, 2023, is entered into by BeiGene, Ltd., a Cayman Islands exempted company (the “Company”), and Xiaodong Wang (the “Consultant”). WHEREAS, the Company desires to retain the services of the Consultant and the Consultant desires to perform certain services for the Company on a consulting |
|
| February 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37 |
|
| February 26, 2024 |
Special Trading Procedures for Insiders Exhibit 19.2 BEIGENE, LTD. SPECIAL TRADING PROCEDURES FOR INSIDERS To comply with federal and state securities laws of the United States, the Hong Kong Model Code for Securities Dealings by Directors of Listed Issuers (the “Model Code”) set out in Appendix 10 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and certain provisions of the Securities and Fut |
|
| February 26, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): February 26, 2024 BEIGENE, LTD. (Exact Name of Registrant as Specified in Charter) Cayman Islands 001-37686 98-1209416 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| February 9, 2024 |
HK:6160 / BeiGene, Ltd. / Capital International Investors - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* BeiGene, Ltd. (Name of Issuer) Common Stock (Title of Class of Securities) G1146Y101 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig |
|
| February 5, 2024 |
BGNE / BeiGene, Ltd. - Depositary Receipt (Common Stock) / OYLER JOHN - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7)* BeiGene, Ltd. (Name of Issuer) Ordinary Shares, par value $0.0001 per share (Title of Class of Securities) 07725L102** (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| January 23, 2024 |
BeiGene Welcomes Experienced Life Sciences Executive Olivier Brandicourt to Board of Directors Exhibit 99.1 BeiGene Welcomes Experienced Life Sciences Executive Olivier Brandicourt to Board of Directors BASEL, Switzerland; BEIJING; and CAMBRIDGE, Mass. – (BUSINESS WIRE) - BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that Olivier Brandicourt, M.D. has been appointed to its Board of Directors. Dr. Brandicourt will join the audit commi |
|
| January 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): January 22, 2024 BEIGENE, LTD. (Exact Name of Registrant as Specified in Charter) Cayman Islands 001-37686 98-1209416 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| December 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): December 7, 2023 BEIGENE, LTD. (Exact Name of Registrant as Specified in Charter) Cayman Islands 001-37686 98-1209416 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| November 14, 2023 |
BGNE / BeiGene Ltd - ADR / BAKER BROS. ADVISORS LP - SC 13D/A Activist Investment SC 13D/A 1 tm2330763d1sc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 10)* BeiGene, Ltd. (Name of Issuer) Ordinary Shares, par value $0.0001 per share (Title of Class of Securities) 07725L102** (CUSIP |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37686 BEIGE |
